These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 15048068

  • 1. Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571.
    Mazzacurati L, Pattacini L, Brusa G, Mancini M, Benvenuti M, Barbieri E, Martinelli G, Baccarani M, Greenberger JS, Santucci MA.
    Hematol J; 2004; 5(2):168-77. PubMed ID: 15048068
    [Abstract] [Full Text] [Related]

  • 2. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S.
    Cancer Res; 2002 Jan 01; 62(1):188-99. PubMed ID: 11782377
    [Abstract] [Full Text] [Related]

  • 3. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
    Sun X, Layton JE, Elefanty A, Lieschke GJ.
    Blood; 2001 Apr 01; 97(7):2008-15. PubMed ID: 11264165
    [Abstract] [Full Text] [Related]

  • 4. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
    Brusa G, Benvenuti M, Mazzacurati L, Mancini M, Pattacini L, Martinelli G, Barbieri E, Greenberger JS, Baccarani M, Santucci MA.
    Haematologica; 2003 Jun 01; 88(6):622-30. PubMed ID: 12801837
    [Abstract] [Full Text] [Related]

  • 5. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M.
    Cancer; 2004 Apr 01; 100(7):1459-71. PubMed ID: 15042680
    [Abstract] [Full Text] [Related]

  • 6. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
    Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Pioltelli P, Pogliani E, Corneo G, Formelli F, D'Incalci M.
    J Natl Cancer Inst; 2000 Oct 18; 92(20):1641-50. PubMed ID: 11036109
    [Abstract] [Full Text] [Related]

  • 7. Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.
    Deutsch E, Maggiorella L, Wen B, Bonnet ML, Khanfir K, Frascogna V, Turhan AG, Bourhis J.
    Br J Cancer; 2004 Nov 01; 91(9):1735-41. PubMed ID: 15494718
    [Abstract] [Full Text] [Related]

  • 8. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
    Mancini M, Petta S, Martinelli G, Barbieri E, Santucci MA.
    J Cell Biochem; 2010 Feb 01; 109(2):320-8. PubMed ID: 20014066
    [Abstract] [Full Text] [Related]

  • 9. Treatment of chronic myeloid leukemia cells with imatinib (STI571) impairs p53 accumulation in response to DNA damage.
    Goldberg Z, Levav Y, Krichevsky S, Fibach E, Haupt Y.
    Cell Cycle; 2004 Sep 01; 3(9):1188-95. PubMed ID: 15467443
    [Abstract] [Full Text] [Related]

  • 10. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C.
    Blood; 2005 Apr 15; 105(8):3303-11. PubMed ID: 15626746
    [Abstract] [Full Text] [Related]

  • 11. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
    Wolff NC, Ilaria RL.
    Blood; 2001 Nov 01; 98(9):2808-16. PubMed ID: 11675355
    [Abstract] [Full Text] [Related]

  • 12. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
    Deininger MW, Vieira SA, Parada Y, Banerji L, Lam EW, Peters G, Mahon FX, Köhler T, Goldman JM, Melo JV.
    Cancer Res; 2001 Nov 01; 61(21):8005-13. PubMed ID: 11691826
    [Abstract] [Full Text] [Related]

  • 13. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
    Liu JH, Liu CC, Yen CC, Gau JP, Wang WS, Tzeng CH.
    Int J Cancer; 2009 Jul 01; 125(1):71-7. PubMed ID: 19291793
    [Abstract] [Full Text] [Related]

  • 14. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J.
    Mutat Res; 2006 Jan 31; 603(1):74-82. PubMed ID: 16388976
    [Abstract] [Full Text] [Related]

  • 15. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
    Topaly J, Zeller WJ, Fruehauf S.
    Leukemia; 2001 Mar 31; 15(3):342-7. PubMed ID: 11237055
    [Abstract] [Full Text] [Related]

  • 16. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606.
    Mancini M, Brusa G, Zuffa E, Corrado P, Martinelli G, Grafone T, Barbieri E, Santucci MA.
    Leuk Res; 2007 Jul 31; 31(7):979-87. PubMed ID: 17129604
    [Abstract] [Full Text] [Related]

  • 17. ARG tyrosine kinase activity is inhibited by STI571.
    Okuda K, Weisberg E, Gilliland DG, Griffin JD.
    Blood; 2001 Apr 15; 97(8):2440-8. PubMed ID: 11290609
    [Abstract] [Full Text] [Related]

  • 18. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
    Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L, Majchrzak B, Ravandi F, Tallman MS, Fish EN, Platanias LC.
    J Biol Chem; 2004 Jun 11; 279(24):25345-52. PubMed ID: 15056660
    [Abstract] [Full Text] [Related]

  • 19. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E.
    Med Klin (Munich); 2002 Jan 15; 97 Suppl 1():2-6. PubMed ID: 11831067
    [Abstract] [Full Text] [Related]

  • 20. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
    Nakajima M, Toga W.
    Nihon Yakurigaku Zasshi; 2003 Dec 15; 122(6):482-90. PubMed ID: 14639002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.